Oxford Scientists Initiates First Human Trials For Deadly Nipah Virus Vaccine

In an unprecedented initiative, researchers University of Oxford in the United Kingdom has started First human vaccine trial for deadly Nipah virus, This initiative is an important step towards addressing the severe impact of the virus on various Asian countries, including India. The trials will be conducted on 51 individuals aged 18 to 55 and will be led by the Oxford Vaccine Group.

ChAdOx1 NipahB Vaccine: A Ray of Hope

experimental vaccine, named ChAdOx1 NipahB, It aims to tackle the Nipah virus, a highly fatal disease with a mortality rate of around 75%. Nipah virus has been responsible for spread in several Asian countries, such as Singapore, Malaysia, Bangladesh and India. Notably, the most recent outbreak occurred in Kerala in September last year.

Understanding Nipah Virus Transmission

Scientists have identified fruit bats as carriers of Nipah virus. Transmission can also occur through Contact with infected animals, such as pigs, or from person to person through close contact, Given the severity of the virus and the rapid spread of the infection, urgent research is deemed necessary.

Nipah virus: a priority disease recognized by WHO

Similar to measles, Nipah virus belongs to the paramyxovirus family. It has been classified by the World Health Organization (WHO) as a priority disease that requires immediate attention and research., Despite first outbreaks in Malaysia and Singapore 25 years ago, there is currently no approved vaccine or treatment for Nipah virus.

Nipah virus: a priority epidemic pathogen

Due to its high mortality rate and mode of transmission, Nipah virus is recognized as a priority epidemic pathogen. Vaccine testing marks an important milestone Look for a Preventive SolutionNot only to thwart local outbreaks but also to prepare for a potential global pandemic.

CEPI’s role in funding the trial

in-kyu yoonActing Executive Director of Vaccine Research and Development Coalition for Epidemic Preparedness Innovations (CEPI), the funder of the trial, highlighted the pandemic potential of Nipah. He stressed the importance of the test as a step toward developing tools to protect against this deadly virus and potentially inform the development of countermeasures for other paramyxoviruses.

Leveraging the ChAdOx1 Platform

Experimental vaccine uses this ChAdOx1 platform, The same viral vector vaccine platform that proved successful in the development of the Oxford/AstraZeneca COVID-19 vaccine. This strategic approach leverages past success to address a new and challenging viral threat.

The way forward: 18 months of research

Nipah vaccine project is Expected to run in the next 18 months, researchers anticipate further trials in the Nipah-hit country. The results of these trials promise to provide much-needed protection against Nipah virus, offering hope for communities vulnerable to this deadly pathogen.

Important questions related to exam

Q1. What is the primary carrier of Nipah virus?

Q2. Which organization recognizes Nipah virus as a priority disease requiring urgent research?

Q3. Which organization is funding the Nipah vaccine trials?

Please share your feedback in the comments section.

Oxford scientists begin first human trial of deadly Nipah virus vaccine_40.1

Leave a Comment